UpFront Diagnostics

UpFront Diagnostics is a private, clinical-stage diagnostics company developing LVOne, a rapid point-of-care blood test for Large Vessel Occlusion (LVO) stroke. The test leverages a proprietary combination of the biomarkers D-dimer and GFAP to deliver results within 10 minutes using a drop of capillary blood, validated in over 500 patients across the UK's National Health Service. The company is pre-revenue, having secured significant venture funding and public grants, and is advancing towards CE Mark approval and commercial launch. Its technology aims to transform the stroke care pathway by enabling diagnosis in ambulances and urgent care settings, potentially reducing time to critical thrombectomy treatment.

Proprietary lateral flow assay combining D-dimer and GFAP biomarkers for rapid point-of-care detection of brain injury, specifically Large Vessel Occlusion (LVO) stroke.

Direct competition in the rapid blood-based LVO detection space appears limited, giving UpFront a potential first-mover advantage. However, competition exists from the current standard of care (hospital-based CT angiography) and emerging technologies like portable stroke detection devices or MRI units. Other companies may be developing biomarker tests for stroke, but LVOne's specific D-dimer/GFAP combination and clinical validation in the NHS provide differentiation.